Journalist

Kim Dong-young
Kim Dong-young김동영
ReporterSamsung Biologics, CJ CheilJedang, LG Chem, Celltrion, Naver, Krafton, Nexon, Hyundai Mobis etc. & energy, game, food, bio, petrochemical, AI
Kim Dong-young is a bilingual journalist at AJU Press (AJP), covering Korean tech, energy, and bio/pharma.
He reports from the field at events like CES and APEC, runs AJP's YouTube channels,
and is pursuing a master's at Sogang's MOT program. "I try everything in this AI era that can improve yet preserve the facts. Journalism still serves as my core."
Samsung, Hyundai, LG and SK chart AI-driven growth strategies for 2026 Samsung, Hyundai, LG and SK chart AI-driven growth strategies for 2026

Samsung, Hyundai, LG and SK chart AI-driven growth strategies for 2026

Korean seaweed rides high as U.S. tariff exemption adds fuel to export boom Korean seaweed rides high as U.S. tariff exemption adds fuel to export boom

Korean seaweed rides high as U.S. tariff exemption adds fuel to export boom

Seoul mayor slams government housing curbs, demands regulatory relief Seoul mayor slams government housing curbs, demands regulatory relief

Seoul mayor slams government housing curbs, demands regulatory relief

Samsung C&T partners with Polands Synthos to expand SMR business in Europe Samsung C&T partners with Poland's Synthos to expand SMR business in Europe

Samsung C&T partners with Poland's Synthos to expand SMR business in Europe

Coupang user numbers rebound slightly despite massive data breach affecting 33.7 million accounts Coupang user numbers rebound slightly despite massive data breach affecting 33.7 million accounts

Coupang user numbers rebound slightly despite massive data breach affecting 33.7 million accounts

SK On–Ford breakup signals Koreas battery pivot to ESS amid EV fog SK On–Ford breakup signals Korea's battery pivot to ESS amid EV fog

SK On–Ford breakup signals Korea's battery pivot to ESS amid EV fog

Celltrion secures major U.S. formulary deal for biosimilar Avtozma Celltrion secures major U.S. formulary deal for biosimilar Avtozma

Celltrion secures major U.S. formulary deal for biosimilar Avtozma

Korea scales back corporate contenders for CES 2026, but books 60% of awards Korea scales back corporate contenders for CES 2026, but books 60% of awards

Korea scales back corporate contenders for CES 2026, but books 60% of awards

Naver launches digital warranty service to combat counterfeits in e-commerce Naver launches digital warranty service to combat counterfeits in e-commerce

Naver launches digital warranty service to combat counterfeits in e-commerce

Korean bio names expand footprint in Japan after cracking open the toughest market in Asia Korean bio names expand footprint in Japan after cracking open the toughest market in Asia

Korean bio names expand footprint in Japan after cracking open the toughest market in Asia